

Martin L Miller

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8694606/martin-l-miller-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39 papers	15,026 citations	25 h-index	43 g-index
43 ext. papers	19,128 ext. citations	18.5 avg, IF	5.86 L-index

#	Paper	IF	Citations
39	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021 , 124, 1759-1776	8.7	19
38	Copy number aberrations drive kinase rewiring, leading to genetic vulnerabilities in cancer. <i>Cell Reports</i> , 2021 , 35, 109155	10.6	0
37	Ovarian tumors orchestrate distinct cellular compositions. <i>Immunity</i> , 2021 , 54, 1107-1109	32.3	1
36	Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. <i>Nature Genetics</i> , 2020 , 52, 582-593	36.3	64
35	Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	7
34	Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases. <i>Nature Communications</i> , 2020 , 11, 4306	17.4	12
33	UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. <i>Cell</i> , 2019 , 179, 219-235	56.2	143
32	Centriolar satellites are acentriolar assemblies of centrosomal proteins. <i>EMBO Journal</i> , 2019 , 38, e101082	10.1	26
31	Comprehensive Benchmarking and Integration of Tumor Microenvironment Cell Estimation Methods. <i>Cancer Research</i> , 2019 , 79, 6238-6246	10.1	38
30	Lack of detectable neoantigen depletion signals in the untreated cancer genome. <i>Nature Genetics</i> , 2019 , 51, 1741-1748	36.3	30
29	Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease-Associated Colorectal Cancers. <i>Clinical Cancer Research</i> , 2018 , 24, 5133-5142	12.9	17
28	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. <i>Cell</i> , 2017 , 170, 927-938.e20	56.2	267
27	Integrin- β 10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma. <i>Cancer Discovery</i> , 2016 , 6, 1148-1165	24.4	40
26	MutationAligner: a resource of recurrent mutation hotspots in protein domains in cancer. <i>Nucleic Acids Research</i> , 2016 , 44, D986-91	20.1	11
25	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015 , 161, 1681-96	56.2	1807
24	Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015 , 348, 124-8	33.3	5003
23	Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. <i>Cell Systems</i> , 2015 , 1, 197-209	10.6	72

22	Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. <i>Journal of Immunology</i> , 2015 , 194, 2089-98	5.3	33
21	KinomeXplorer: an integrated platform for kinome biology studies. <i>Nature Methods</i> , 2014 , 11, 603-4	21.6	196
20	Spatial normalization of reverse phase protein array data. <i>PLoS ONE</i> , 2014 , 9, e97213	3.7	18
19	Cell-selective labeling using amino acid precursors for proteomic studies of multicellular environments. <i>Nature Methods</i> , 2013 , 10, 768-73	21.6	38
18	The Cancer Genome Atlas Pan-Cancer analysis project. <i>Nature Genetics</i> , 2013 , 45, 1113-20	36.3	3933
17	Emerging landscape of oncogenic signatures across human cancers. <i>Nature Genetics</i> , 2013 , 45, 1127-33	36.3	889
16	The SH2 domain interaction landscape. <i>Cell Reports</i> , 2013 , 3, 1293-305	10.6	89
15	Perturbation biology: inferring signaling networks in cellular systems. <i>PLoS Computational Biology</i> , 2013 , 9, e1003290	5	98
14	Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. <i>Science Signaling</i> , 2013 , 6, ra85	8.8	61
13	Meta-analysis of heterogeneous data sources for genome-scale identification of risk genes in complex phenotypes. <i>Genetic Epidemiology</i> , 2011 , 35, 318-32	2.6	28
12	Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. <i>Science Signaling</i> , 2010 , 3, ra3	8.8	1106
11	NetPhosBac - a predictor for Ser/Thr phosphorylation sites in bacterial proteins. <i>Proteomics</i> , 2009 , 9, 116-25	4.8	55
10	Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. <i>Nature Biotechnology</i> , 2009 , 27, 549-55	44.5	393
9	Kinase-specific prediction of protein phosphorylation sites. <i>Methods in Molecular Biology</i> , 2009 , 527, 299-310, x	1.4	43
8	Motif decomposition of the phosphotyrosine proteome reveals a new N-terminal binding motif for SHIP2. <i>Molecular and Cellular Proteomics</i> , 2008 , 7, 181-92	7.6	13
7	Linear motif atlas for phosphorylation-dependent signaling. <i>Science Signaling</i> , 2008 , 1, ra2	8.8	342
6	NetPhosYeast: prediction of protein phosphorylation sites in yeast. <i>Bioinformatics</i> , 2007 , 23, 895-7	7.2	103
5	Characterization and location of secretory phospholipase A2 groups IIE, V, and X in the rat brain. <i>Journal of Neuroscience Research</i> , 2006 , 83, 874-82	4.4	21

4	Unraveling Tumor-Immune Heterogeneity in Advanced Ovarian Cancer Uncovers Immunogenic Effect of Chemotherapy	2
3	Lack of detectable neoantigen depletion in the untreated cancer genome	4
2	Computed Tomography Measures of Inter-site tumor Heterogeneity for Classifying Outcomes in High-Grade Serous Ovarian Carcinoma: a Retrospective Study	2
1	Multi-site clonality analyses uncovers pervasive subclonal heterogeneity and branching evolution across melanoma metastases	2